Joseph P. Hagan
2012 - Orexigen Therapeutics
In 2012, Joseph P. Hagan earned a total compensation of $1.3M as Chief Business and Financial Officer at Orexigen Therapeutics, a 39% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $222,000 |
|---|---|
| Option Awards | $655,795 |
| Salary | $370,000 |
| Other | $7,620 |
| Total | $1,255,415 |
Hagan received $655.8K in option awards, accounting for 52% of the total pay in 2012.
Hagan also received $222K in non-equity incentive plan, $370K in salary and $7.6K in other compensation.
Rankings
In 2012, Joseph P. Hagan's compensation ranked 5,239th out of 11,487 executives tracked by ExecPay. In other words, Hagan earned more than 54.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,239 out of 11,487 | 54th |
Division Manufacturing | 1,834 out of 4,253 | 57th |
Major group Chemicals And Allied Products | 441 out of 1,198 | 63rd |
Industry group Drugs | 288 out of 920 | 69th |
Industry Pharmaceutical Preparations | 226 out of 700 | 68th |
Source: SEC filing on April 22, 2015.
Hagan's colleagues
We found four more compensation records of executives who worked with Joseph P. Hagan at Orexigen Therapeutics in 2012.
2012
Michael Narachi
Orexigen Therapeutics
Chief Executive Officer
2012
Preston Klassen
Orexigen Therapeutics
Head of Global Contrave Program and Executive Vice President, Product Development
2012
Heather Turner
Orexigen Therapeutics
General Counsel
2012
Mark Booth
Orexigen Therapeutics
Chief Commercial Officer outgoing
News
Regulus Therapeutics CEO Joseph Hagan's 2021 pay falls 22% to $1.8M
April 27, 2022
Regulus Therapeutics CEO Joseph Hagan's 2020 pay rises 16% to $2.3M
April 30, 2021
Regulus Therapeutics CEO Joseph Hagan's 2019 pay slips 14% to $2M
April 29, 2020
Regulus Therapeutics CEO Joseph Hagan's 2018 pay jumps 22% to $2.3M
July 1, 2019